MicroRNA‑877 acts as a tumor suppressor by directly targeting eEF2K in renal cell carcinoma

Shi,Qianqian; Xu,Xianlin; Liu,Qing; Luo,Fengbao; Shi,Jian; He,Xiaozhou

doi:10.3892/ol.2015.4072

MicroRNA‑877 acts as a tumor suppressor by directly targeting eEF2K in renal cell carcinoma

Authors:
- Qianqian Shi
- Xianlin Xu
- Qing Liu
- Fengbao Luo
- Jian Shi
- Xiaozhou He
View Affiliations

Affiliations: Department of Urology, The Third Affiliated Hospital of Soochow University, Changzhou, Jiangsu 213000, P.R. China
Published online on: December 31, 2015 https://doi.org/10.3892/ol.2015.4072
Pages: 1474-1480

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

MicroRNAs (miRNAs) are involved in tumorigenesis. However, little is known about their role in renal cell carcinoma (RCC). In the present study, the function of the miRNA miR‑877 in RCC was investigated, and its expression levels in blood and paired RCC tissues were measured by reverse transcription‑quantitative polymerase chain reaction (RT‑qPCR). Bioinformatics analysis predicted eukaryotic elongation factor‑2 kinase (eEF2K) to be the potential mRNA target of miR‑877, which was verified by luciferase assay. The expression levels of eEF2K in RCC tissues were evaluated by western blot analysis and qPCR. The proliferation and migration abilities of RCC cells were measured by MTT and in vitro wound healing assays, respectively. The present results indicated that the expression levels of miR‑877 were downregulated in blood and paired RCC tissues, whereas the expression levels of eEF2K were upregulated in RCC tissues. In addition, overexpression of miR‑877 and knockdown of eEF2K significantly reduced the proliferation and migration abilities of RCC cells in vitro. Furthermore, miR‑877 affected the eEF2K/eEF2 signaling pathway in these cells. In conclusion, the present study has demonstrated that miR‑877 suppresses the proliferation and migration abilities of RCC cells by modulating the eEF2K/eEF2 signaling cascade. Therefore, miR‑877 may be considered a potential biomarker for the diagnosis of RCC.

View Figures

View References

1	Tong AW and Nemunaitis J: Modulation of miRNA activity in human cancer: A new paradigm for cancer gene therapy? Cancer Gene Ther. 15:341–355. 2008. View Article : Google Scholar : PubMed/NCBI
2	Yu Z, Jian Z, Shen SH, Purisima E and Wang E: Global analysis of microRNA target gene expression reveals that miRNA targets are lower expressed in mature mouse and Drosophila tissues than in the embryos. Nucleic Acids Res. 35:152–164. 2007. View Article : Google Scholar : PubMed/NCBI
3	Steffens S, Roos FC, Janssen M, Becker F, Steinestel J, Abbas M, Steinestel K, Wegener G, Siemer S, Thüroff JW, et al: German Renal Cell Cancer Network: Clinical behavior of chromophobe renal cell carcinoma is less aggressive than that of clear cell renal cell carcinoma, independent of Fuhrman grade or tumor size. Virchows Arch. 465:439–444. 2014. View Article : Google Scholar : PubMed/NCBI
4	Doehn C, Witzsch U and Siebels M: Active surveillance for renal cell carcinoma. Aktuelle Urol. 43:243–249. 2012.(In German). PubMed/NCBI
5	Chen T, Fallah M, Sundquist K, Liu H and Hemminki K: Risk of subsequent cancers in renal cell carcinoma survivors with a family history. Eur J Cancer. 50:2108–2118. 2014. View Article : Google Scholar : PubMed/NCBI
6	Hew MN, Zonneveld R, Kümmerlin IP, Opondo D, de la Rosette JJ and Laguna MP: Age and gender related differences in renal cell carcinoma in a European cohort. J Urol. 188:33–38. 2012. View Article : Google Scholar : PubMed/NCBI
7	Cairns P: Renal cell carcinoma. Cancer Biomark. 9:461–473. 2010.PubMed/NCBI
8	Olshan AF, Kuo TM, Meyer AM, Nielsen ME, Purdue MP and Rathmell WK: Racial difference in histologic subtype of renal cell carcinoma. Cancer Med. 2:744–749. 2013.PubMed/NCBI
9	Banyra O, Tarchynets M and Shulyak A: Renal cell carcinoma: How to hit the targets? Cent European J Urol. 66:394–404. 2014.PubMed/NCBI
10	Ngo TC, Wood CG and Karam JA: Biomarkers of renal cell carcinoma. Urol Oncol. 32:243–251. 2014. View Article : Google Scholar : PubMed/NCBI
11	White NM, Khella HW, Grigull J, Adzovic S, Youssef YM, Honey RJ, Stewart R, Pace KT, Bjarnason GA, Jewett MA, et al: miRNA profiling in metastatic renal cell carcinoma reveals a tumor-suppressor effect for miR-215. Br J Cancer. 105:1741–1749. 2011. View Article : Google Scholar : PubMed/NCBI
12	Beresneva EV, Rykov SV, Hodyrev DS, Pronina IV, Ermilova VD, Kazubskaia TP, Braga EA and Loginov VI: Methylation profile of group of miRNA genes in clear cell renal cell carcinoma; involvement in cancer progression. Genetika. 49:366–375. 2013.(In Russian). PubMed/NCBI
13	Mei Q, Li X, Guo M, Fu X and Han W: The miRNA network: Micro-regulator of cell signaling in cancer. Expert Rev Anticancer Ther. 14:1515–1527. 2014. View Article : Google Scholar : PubMed/NCBI
14	Filip A: MiRNA - new mechanisms of gene expression control. Postepy Biochem. 53:413–419. 2007.(In Polish). PubMed/NCBI
15	Cheng AM, Byrom MW, Shelton J and Ford LP: Antisense inhibition of human miRNAs and indications for an involvement of miRNA in cell growth and apoptosis. Nucleic Acids Res. 33:1290–1297. 2005. View Article : Google Scholar : PubMed/NCBI
16	Giannakakis A, Coukos G, Hatzigeorgiou A, Sandaltzopoulos R and Zhang L: miRNA genetic alterations in human cancers. Expert Opin Biol Ther. 7:1375–1386. 2007. View Article : Google Scholar : PubMed/NCBI
17	Mezzanzanica D, Canevari S, Cecco LD and Bagnoli M: miRNA control of apoptotic programs: Focus on ovarian cancer. Expert Rev Mol Diagn. 11:277–286. 2011.PubMed/NCBI
18	Rose AJ, Alsted TJ, Jensen TE, Kobberø JB, Maarbjerg SJ, Jensen J and Richter EA: A Ca⁽²⁺⁾-calmodulin-eEF2K-eEF2 signalling cascade, but not AMPK, contributes to the suppression of skeletal muscle protein synthesis during contractions. J Physiol. 587:1547–1563. 2009. View Article : Google Scholar : PubMed/NCBI
19	Fu LL, Xie T, Zhang SY and Liu B: Eukaryotic elongation factor-2 kinase (eEF2K): A potential therapeutic target in cancer. Apoptosis. 19:1527–1531. 2014. View Article : Google Scholar : PubMed/NCBI
20	Arora S, Yang JM, Kinzy TG, Utsumi R, Okamoto T, Kitayama T, Ortiz PA and Hait WN: Identification and characterization of an inhibitor of eukaryotic elongation factor 2 kinase against human cancer cell lines. Cancer Res. 63:6894–6899. 2003.PubMed/NCBI
21	Xie CM, Liu XY, Sham KW, Lai JM and Cheng CH: Silencing of EEF2K (eukaryotic elongation factor-2 kinase) reveals AMPK-ULK1-dependent autophagy in colon cancer cells. Autophagy. 10:1495–1508. 2014. View Article : Google Scholar : PubMed/NCBI
22	Zhu H, Yang X, Liu J, Zhou L, Zhang C, Xu L, Qin Q, Zhan L, Lu J, Cheng H and Sun X: Eukaryotic elongation factor 2 kinase confers tolerance to stress conditions in cancer cells. Cell Stress Chaperones. 20:217–220. 2014. View Article : Google Scholar : PubMed/NCBI
23	Liu B, Cheng Y, Liu Q, Bao JK and Yang M: Autophagic pathways as new targets for cancer drug development. Acta Pharmacol Sin. 31:1154–1164. 2010. View Article : Google Scholar : PubMed/NCBI
24	Tekedereli I, Alpay SN, Tavares CD, Cobanoglu ZE, Kaoud TS, Sahin I, Sood AK, Lopez-Berestein G, Dalby KN and Ozpolat B: Targeted silencing of elongation factor 2 kinase suppresses growth and sensitizes tumors to doxorubicin in an orthotopic model of breast cancer. PLoS One. 7:e411712012. View Article : Google Scholar : PubMed/NCBI
25	Chen Y, Zhu X, Zhang X, Liu B and Huang L: Nanoparticles modified with tumor-targeting scFv deliver siRNA and miRNA for cancer therapy. Mol Ther. 18:1650–1656. 2010. View Article : Google Scholar : PubMed/NCBI
26	Qi M, Huang X, Zhou L and Zhang J: Identification of differentially expressed microRNAs in metastatic melanoma using next-generation sequencing technology. Int J Mol Med. 33:1117–1121. 2014.PubMed/NCBI
27	Kruger NJ: The Bradford method for protein quantitation. Basic Protein and Peptide Protocols. Walker JM: 32:(Totowa, NJ). Humana Press. 9–15. 1994. View Article : Google Scholar
28	Creel PA: Optimizing patient adherence to targeted therapies in renal cell carcinoma. Clin J Oncol Nurs. 18:694–700. 2014. View Article : Google Scholar : PubMed/NCBI
29	Chen C, Ai H, Ren J, Li W, Li P, Qiao R, Ouyang J, Yang M, Ma J and Huang L: A global view of porcine transcriptome in three tissues from a full-sib pair with extreme phenotypes in growth and fat deposition by paired-end RNA sequencing. BMC Genomics. 12:4482011. View Article : Google Scholar : PubMed/NCBI
30	Lyons PJ, Lang-Ouellette D and Morin P Jr: CryomiRs: Towards the identification of a cold-associated family of microRNAs. Comp Biochem Physiol Part D Genomics Proteomics. 8:358–364. 2013. View Article : Google Scholar : PubMed/NCBI
31	Kosaka N, Iguchi H and Ochiya T: Circulating microRNA in body fluid: A new potential biomarker for cancer diagnosis and prognosis. Cancer Sci. 101:2087–2092. 2010. View Article : Google Scholar : PubMed/NCBI
32	Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK, Pogosova-Agadjanyan EL, Peterson A, Noteboom J, O'Briant KC, Allen A, et al: Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci USA. 105:10513–10518. 2008. View Article : Google Scholar : PubMed/NCBI
33	Huang Y, Dai Y, Yang J, Chen T, Yin Y, Tang M, Hu C and Zhang L: Microarray analysis of microRNA expression in renal clear cell carcinoma. Eur J Surg Oncol. 35:1119–1123. 2009. View Article : Google Scholar : PubMed/NCBI
34	Zhang H, Guo Y, Shang C, Song Y and Wu B: miR-21 downregulated TCF21 to inhibit KISS1 in renal cancer. Urology. 80:1298–1302. 2012. View Article : Google Scholar : PubMed/NCBI
35	Kloosterman WP and Plasterk RH: The diverse functions of microRNAs in animal development and disease. Dev Cell. 11:441–450. 2006. View Article : Google Scholar : PubMed/NCBI
36	Shenouda SK and Alahari SK: MicroRNA function in cancer: Oncogene or a tumor suppressor? Cancer Metastasis Rev. 28:369–378. 2009. View Article : Google Scholar : PubMed/NCBI
37	Ventura A and Jacks T: MicroRNAs and cancer: Short RNAs go a long way. Cell. 136:586–591. 2009. View Article : Google Scholar : PubMed/NCBI
38	Knebel A, Haydon CE, Morrice N and Cohen P: Stress-induced regulation of eukaryotic elongation factor 2 kinase by SB 203580-sensitive and -insensitive pathways. Biochem J. 367:525–532. 2002. View Article : Google Scholar : PubMed/NCBI